Live tape
Top 8, mentions 7d9,514GOOGL1,899 mentions▲ +0.04SNDK1,548 mentions▲ +0.11NVDA1,168 mentions▲ +0.08META1,148 mentions▲ +0.03SPCX1,096 mentions▲ +0.08NBIS984 mentions▲ +0.09HTZ857 mentions▲ +0.09VOO814 mentions▲ +0.09

Equity · Healthcare

ESPR

Esperion Therapeutics, Inc. · NasdaqGM

$3.19 +0.16% 1D Finazon · prior-day close · Jul 10, 2026
Price · Chart
Our own end-of-day closes 34 sessions
$3.200 $3.100 21 May 10 Jul

The line runs $3.13 on 21 May through $3.19 on 10 July, on a scale from $3.100 to $3.200. Days the market did not trade hold the previous close, flat.

The chart above plots the price of ESPR over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 34 sessions over that window: $3.13 on 21 May 2026 through $3.19 on 10 July 2026.

Market cap $821.2M
52-week range $1.11 – $4.08
Avg volume 2.0M

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 19, 2026

ESPR insider trades

SEC Form 4 · last 90 days · newest reported trade 17 Jun 2026
Open-market buys 0
Open-market sells 3
Net sold $240K
Non-trade filings 14
Date Insider Type Shares Value
17 Jun 2026 Halladay Benjamin Chief Financial Officer Sell 10,773 $34K
17 Jun 2026 Koenig Sheldon L. President and CEO Sell 53,588 $169K
17 Jun 2026 Looker Benjamin Chief Legal Officer Sell 11,824 $37K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
13 Jul 2026 CARROLL J MARTIN Director Other 177,523
13 Jul 2026 Koenig Sheldon L. President and CEO Other 2,121,094
13 Jul 2026 Halladay Benjamin Chief Financial Officer Other 705,410
13 Jul 2026 Looker Benjamin Chief Legal Officer Other 667,524
13 Jul 2026 Harlow John B. Jr. Chief Commercial Officer Other 424,536
13 Jul 2026 THOMPSON JOHN CRAIG Director Other 79,873
13 Jul 2026 Fischer Seth H. Z. Director Other 141,023
13 Jul 2026 Shepard Jay Director Other 164,472
13 Jul 2026 Hoffman Robert E. Director Other 85,153
28 May 2026 CARROLL J MARTIN Director Award 79,873
28 May 2026 Fischer Seth H. Z. Director Award 79,873
28 May 2026 Hoffman Robert E. Director Award 79,873

Showing the 12 most recent of 14 compensation filings in this window. The figures above count all of them.

ESPR earnings

SEC EDGAR
Date Period EPS Revenue
31 Mar 2026 Q1 2026 $-0.10 $80M
31 Dec 2025 FY 2025 $-0.11 $403M
30 Sep 2025 Q3 2025 $-0.16 $87M
30 Jun 2025 Q2 2025 $-0.06 $82M
31 Mar 2025 Q1 2025 $-0.21 $65M
31 Dec 2024 FY 2024 $-0.28 $332M
30 Sep 2024 Q3 2024 $-0.15 $52M
30 Jun 2024 Q2 2024 $-0.33 $74M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ESPR institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a ESPR position for the quarter ended 30 Jun 2026 — a combined $49.2M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Two Sigma Investments Held (±25%) −24.7% shares 7,126,739 $22.5M
Balyasny Asset Management New position 4,654,778 $14.7M
Millennium Management Added +268.3% shares 2,225,733 $7.0M
Soros Fund Management New position 757,358 $2.4M
Citadel Advisors Held (±25%) −1.3% shares 461,649 $1.5M
GAMCO Investors New position 172,500 $545K
Renaissance Technologies Trimmed −90.1% shares 160,200 $506K
Marshall Wace Trimmed −99.8% shares 14,118 $45K

Source: SEC EDGAR 13F filings

ESPR fails-to-deliver

SEC CNS data

On 09 Jul 2026, 43,283 shares of ESPR failed to deliver (about $138K) — the latest of at least 4 consecutive trading days with recorded fails. The run reaches the start of the window we read, so it may have begun earlier.

Settlement date Shares failed Notional % of shares out
09 Jul 2026 43,283 $138K 0.017%
08 Jul 2026 53,179 $168K 0.021%
07 Jul 2026 400 $1K <0.001%
06 Jul 2026 9,400 $30K 0.004%

Source: SEC fails-to-deliver (CNS) data